ATHA (Athira Pharma Corp) מכפיל P/S עתידי

Athira Pharma, Inc. (ATHA) is focusing on the expansion of phosphgonimetone to combat Alzheimer's disease. The GURU.Markets system displays the change in forward P/S, where the current parameter is . Automated molecule screening is accelerating scientific research, while emerging catalysts for the new pipeline, with past failures already priced in, create a foundation for potential growth.

Professional capital evaluates Athira Pharma, Inc. (ATHA) through the lens of strategic pivot risks and the efficacy of second-generation molecule development. The forward P/S ratio compares the issuer's market value with expected revenue, allowing this chart to determine the asset's degree of overvaluation during the cost restructuring period, which is critical for minimizing long-term portfolio drawdowns.